261 related articles for article (PubMed ID: 11741249)
1. CYP2D6 genotyping as an alternative to phenotyping for determination of metabolic status in a clinical trial setting.
McElroy S; Sachse C; Brockmoller J; Richmond J; Lira M; Friedman D; Roots I; Silber BM; Milos PM
AAPS PharmSci; 2000; 2(4):E33. PubMed ID: 11741249
[TBL] [Abstract][Full Text] [Related]
2. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences.
Sachse C; Brockmöller J; Bauer S; Roots I
Am J Hum Genet; 1997 Feb; 60(2):284-95. PubMed ID: 9012401
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping.
Frank D; Jaehde U; Fuhr U
Eur J Clin Pharmacol; 2007 Apr; 63(4):321-33. PubMed ID: 17273835
[TBL] [Abstract][Full Text] [Related]
4. Dose dependency of dextromethorphan for cytochrome P450 2D6 (CYP2D6) phenotyping.
Streetman DS; Ellis RE; Nafziger AN; Leeder JS; Gaedigk A; Gotschall R; Kearns GL; Bertino JS
Clin Pharmacol Ther; 1999 Nov; 66(5):535-41. PubMed ID: 10579482
[TBL] [Abstract][Full Text] [Related]
5. Endoxifen levels and its association with CYP2D6 genotype and phenotype: evaluation of a southern Brazilian population under tamoxifen pharmacotherapy.
Antunes MV; Linden R; Santos TV; Wallemacq P; Haufroid V; Classen JF; Andreolla H; Costa N; Fontanive TO; Rosa DD
Ther Drug Monit; 2012 Aug; 34(4):422-31. PubMed ID: 22777153
[TBL] [Abstract][Full Text] [Related]
6. CYP2D6 genotype and phenotyping by determination of dextromethorphan and metabolites in serum of healthy controls and of patients under psychotropic medication.
Köhler D; Härtter S; Fuchs K; Sieghart W; Hiemke C
Pharmacogenetics; 1997 Dec; 7(6):453-61. PubMed ID: 9429230
[TBL] [Abstract][Full Text] [Related]
7. Correlation of genotype, phenotype, and mRNA expression of CYP2D6 and CYP2C19 in peripheral blood leukocytes (PBLs).
Kuhlmann JB; Wensing G; Kuhlmann J
Int J Clin Pharmacol Ther; 2014 Feb; 52(2):143-50. PubMed ID: 24361088
[TBL] [Abstract][Full Text] [Related]
8. Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans.
Gaedigk A; Bradford LD; Marcucci KA; Leeder JS
Clin Pharmacol Ther; 2002 Jul; 72(1):76-89. PubMed ID: 12152006
[TBL] [Abstract][Full Text] [Related]
9. Serum dextromethorphan/dextrorphan metabolic ratio for CYP2D6 phenotyping in clinical practice.
Jurica J; Bartecek R; Zourkova A; Pindurova E; Sulcova A; Kasparek T; Zendulka O
J Clin Pharm Ther; 2012 Aug; 37(4):486-90. PubMed ID: 22548589
[TBL] [Abstract][Full Text] [Related]
10. Quantification of intraindividual variability and the influence of menstrual cycle phase on CYP2D6 activity as measured by dextromethorphan phenotyping.
Kashuba AD; Nafziger AN; Kearns GL; Leeder JS; Shirey CS; Gotschall R; Gaedigk A; Bertino JS
Pharmacogenetics; 1998 Oct; 8(5):403-10. PubMed ID: 9825832
[TBL] [Abstract][Full Text] [Related]
11. Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers.
Evans WE; Relling MV
Pharmacogenetics; 1991 Dec; 1(3):143-8. PubMed ID: 1688245
[TBL] [Abstract][Full Text] [Related]
12. Prediction of phenotype for dextromethorphan O-demethylation by using polymerase chain reaction in healthy volunteers.
Zimmermann T; Schlenk R; Pfaff G; Lach P; Wildfeuer A
Arzneimittelforschung; 1995 Jan; 45(1):41-3. PubMed ID: 7893267
[TBL] [Abstract][Full Text] [Related]
13. Measurement of CYP2D6 and CYP3A4 activity in vivo with dextromethorphan: sources of variability and predictors of adverse effects in 419 healthy subjects.
Funck-Brentano C; Boëlle PY; Verstuyft C; Bornert C; Becquemont L; Poirier JM
Eur J Clin Pharmacol; 2005 Dec; 61(11):821-9. PubMed ID: 16315033
[TBL] [Abstract][Full Text] [Related]
14. Phenotype and genotype analysis of debrisoquine hydroxylase (CYP2D6) in a black Zimbabwean population. Reduced enzyme activity and evaluation of metabolic correlation of CYP2D6 probe drugs.
Masimirembwa C; Hasler J; Bertilssons L; Johansson I; Ekberg O; Ingelman-Sundberg M
Eur J Clin Pharmacol; 1996; 51(2):117-22. PubMed ID: 8911874
[TBL] [Abstract][Full Text] [Related]
15. Cytochrome P
Dhuya M; Pal MM; Hazra A; Chatterjee S; Gogtay N
Indian J Pharmacol; 2020; 52(3):189-195. PubMed ID: 32874001
[TBL] [Abstract][Full Text] [Related]
16. CYP2D6 phenotyping with dextromethorphan.
Wojtczak A; Rychlik-Sych M; Krochmalska-Ulacha E; Skretkowicz J
Pharmacol Rep; 2007; 59(6):734-8. PubMed ID: 18195464
[TBL] [Abstract][Full Text] [Related]
17. Comparison of three CYP2D6 probe substrates and genotype in Ghanaians, Chinese and Caucasians.
Droll K; Bruce-Mensah K; Otton SV; Gaedigk A; Sellers EM; Tyndale RF
Pharmacogenetics; 1998 Aug; 8(4):325-33. PubMed ID: 9731719
[TBL] [Abstract][Full Text] [Related]
18. Effect of gender, sex hormones, time variables and physiological urinary pH on apparent CYP2D6 activity as assessed by metabolic ratios of marker substrates.
Labbé L; Sirois C; Pilote S; Arseneault M; Robitaille NM; Turgeon J; Hamelin BA
Pharmacogenetics; 2000 Jul; 10(5):425-38. PubMed ID: 10898112
[TBL] [Abstract][Full Text] [Related]
19. [Assessment of CYP2D6 activity as a form of optimizing antidepressant therapy].
Szewczuk-Bogusławska M; Grzesiak M; Beszłej JA; Kiejna A
Psychiatr Pol; 2004; 38(6):1093-104. PubMed ID: 15779673
[TBL] [Abstract][Full Text] [Related]
20. Polymorphism of dextromethorphan metabolism: relationships between phenotype, genotype and response to the administration of encainide in humans.
Funck-Brentano C; Thomas G; Jacqz-Aigrain E; Poirier JM; Simon T; Béréziat G; Jaillon P
J Pharmacol Exp Ther; 1992 Nov; 263(2):780-6. PubMed ID: 1432700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]